ACP3 and cancer: Indeed, Sipuleucel-T (Provenge), the first FDA-approved therapeutic cancer vaccine, utilizes the treatment of monocyte-derived DCs with a fusion protein of GM-CSF and prostatic acid phosphatase (PAP) antigen67.